Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Pharmaust Limited ( (AU:NUZ) ) just unveiled an update.
Neurizon Therapeutics Limited has applied to the ASX for quotation of 79,330,864 new ordinary fully paid shares, to be issued on 2 January 2026 under code NUZ. The application, lodged as an Appendix 2A, indicates a significant expansion of the company’s quoted share capital, which may influence market liquidity and ownership structure and is linked to transactions previously flagged in an earlier Appendix 3B filing.
The most recent analyst rating on (AU:NUZ) stock is a Buy with a A$0.56 price target. To see the full list of analyst forecasts on Pharmaust Limited stock, see the AU:NUZ Stock Forecast page.
More about Pharmaust Limited
Neurizon Therapeutics Limited is a biotechnology company listed on the ASX under the code NUZ, operating in the therapeutics sector with a focus suggested by its name on developing treatments in the neurology or broader pharmaceutical space.
Average Trading Volume: 793,792
Technical Sentiment Signal: Sell
Current Market Cap: A$66.01M
Find detailed analytics on NUZ stock on TipRanks’ Stock Analysis page.